Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
NOT YET RECRUITING
NCT07865442
PHASE1
First in Human Study of ALT-01 in Healthy Participants
Sponsor: Altis Medicines, Inc
View on ClinicalTrials.gov
Summary
The primary objective of the study is to evaluate the safety and tolerability of ALT-01 in healthy participants
Official title: First in Human, Randomized, Blinded, Placebo-Controlled Single Ascending Dose Study of ALT-01 in Healthy Participants
Key Details
Gender
All
Age Range
18 Years - 65 Years
Study Type
INTERVENTIONAL
Enrollment
50
Start Date
2026-10-26
Completion Date
2027-09-30
Last Updated
2026-10-13
Healthy Volunteers
Yes
Conditions
Interventions
DRUG
ALT-01
Subcutaneous injection
DRUG
Placebo
Subcutaneous injection
Locations (1)
Altis Site
Adelaide, South Australia, Australia